Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
about
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.Cardiovascular safety and benefits of GLP-1 receptor agonists.Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.Semaglutide seems to be more effective the other GLP-1Ras.Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide.Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
P2860
Q38378906-A1186BE6-0CE2-46B3-A870-C345144C855BQ38662690-11B51581-1789-40F8-BFA5-F764D59FB114Q38989309-335CB689-5242-4E93-A119-8E29C862FADCQ39013056-33A8E428-7903-4201-B12C-766A0F70FECDQ40998901-DD7C5D53-D2B6-47C1-A6AB-574A0E01D4B0Q41539948-36DAE5FF-FDDD-4760-BEE6-CE6BB8F88AE3Q43246916-083C532B-4C63-4CD8-9CD5-6A19C4434036Q47114286-2C39697C-9526-41CD-AC00-9D58C80C4337Q47409299-A9894AE0-ABE9-49AB-B3CF-050D102CA787Q48178209-FE590CB2-49D6-4C58-B82A-8A95CBCAE0DFQ48264116-D40882A4-EDF8-4666-A4CB-0442B1A011E4Q48274676-4B2F0FEF-A3AF-46AF-8221-953615E3E0D5Q48300522-0B18D976-80AB-4406-A85A-CD0FECB4E5DFQ52656812-EEA448A0-9D29-43B8-9FCB-C41E253088EBQ55364507-188CE134-135D-483B-8DD5-6FF534601EB3Q55401199-889DC7BB-E2DF-42EA-8EF6-92A532C8E68F
P2860
Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Semaglutide, a once-weekly hum ...... hinylestradiol/levonorgestrel.
@ast
Semaglutide, a once-weekly hum ...... hinylestradiol/levonorgestrel.
@en
type
label
Semaglutide, a once-weekly hum ...... hinylestradiol/levonorgestrel.
@ast
Semaglutide, a once-weekly hum ...... hinylestradiol/levonorgestrel.
@en
prefLabel
Semaglutide, a once-weekly hum ...... hinylestradiol/levonorgestrel.
@ast
Semaglutide, a once-weekly hum ...... hinylestradiol/levonorgestrel.
@en
P2093
P2860
P356
P1476
Semaglutide, a once-weekly hum ...... hinylestradiol/levonorgestrel.
@en
P2093
Anne Flint
Christine B Jensen
Christoph Kapitza
Helle Hartvig
Lene Jensen
Leszek Nosek
P2860
P304
P356
10.1002/JCPH.443
P577
2015-01-14T00:00:00Z